| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | Navitoclax with ruxolitinib - (REFINE) | Myelofibrosis | Phase 2 | Data Released | Oral | Hematology |
| AbbVie Inc. | Mirvetuximab in combination with carboplatin - (0420) | Ovarian cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| AbbVie Inc. | Mirvetuximab - (PICCOLO) | Ovarian cancer | Phase 2 | Data Released | Intravenous | Oncology |
| AbbVie Inc. | NX-13 - (NEXUS) | Ulcerative Colitis (UC) | Phase 2 | Ongoing | Oral | Gastroenterology |
| AbbVie Inc. | NX-13 | Crohn’s Disease | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| AbbVie Inc. | Omilancor (BT-11) | Crohn’s Disease | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| AbbVie Inc. | Omilancor (BT-11) | Ulcerative Colitis | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| AbbVie Inc. | Darigabat (CVL-865) - (REALIZE) | Focal onset epilepsy | Phase 2 | Ongoing | Oral | Neurology |